5 Strategies for Achieving Transparency in Your Pharmacy Contract
How can you build more transparency in your pharmacy contract? We lay out five critical strategies to ensure you have control and oversight over your program.
Webinar - Pharmacy Benefits 101: What Employers Need to Know About PBMs and Drug Spend
In this Truveris webinar, we join Mployer Advisor to tackle pharmacy benefits 101. What should payers know about PBMs as they plan for 2023?
3 Patient Access Strategies Setting Innovative Brands Apart
The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?
7 Indicators that Your Drug is a Strong Candidate for Accumulator and Maximizer Programs
How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.
The Truveris Pharmacy Benefits Glossary of Terms
Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.
3 Patient Access Strategies for New Biosimilar Brands
As biosimilars gain more popularity in the market, pharma manufacturers must think differently about launch strategies to gain market share.
What are Biosimilars and Why Do They Matter?
If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?
6 Takeaways from the Asembia 2022 Specialty Pharmacy Summit
6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?
What Self-Funded Plans Should Know About Copay Assistance Programs
Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?
How to Manage High-Cost Specialty Drug Spend for Self-Funded Plans
As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?
POV - Misaligned Incentives in the Pharmacy Ecosystem
Read Sally Welborn’s POV piece on the misaligned incentives at play in the pharmacy benefits ecosystem – and what it means for plan sponsors.
Webinar - Copay Maximizers and Alternative Funding: What Self-Funded Plans Should Know
How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.
Asembia 2021: Four Key Takeaways
Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.
The 340B Program: How Manufacturers, Plan Sponsors, and Brokers Should React
340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?
Gene Therapy and Cell Therapy: Key Payer Considerations
Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?
Webinar - Payer Strategies for Anticipating and Managing Gene Therapy
Watch Truveris’ on-demand webinar outlining how Payers can best anticipate and manage new gene therapies.
What's the Difference between a Specialty Drug and a Non-Specialty Drug?
Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.
A Truveris Webinar - Managing Specialty Costs: Strategies for Optimizing Your Self-Funded Pharmacy Benefits Program
Watch Truveris’ webinar to learn more about how you can better manage a self-funded specialty pharmacy program.
What is a Pharmacy Benefits Manager (PBM) and How Does a PBM Impact the Pharmacy Benefits Ecosystem?
Pharmacy Benefits Managers, also referred to as PBMs, are the intermediaries between every stakeholder in the pharmacy ecosystem.